138 related articles for article (PubMed ID: 10394541)
21. Cell proliferation and apoptosis in human uterine leiomyomas and myometria.
Dixon D; Flake GP; Moore AB; He H; Haseman JK; Risinger JI; Lancaster JM; Berchuck A; Barrett JC; Robboy SJ
Virchows Arch; 2002 Jul; 441(1):53-62. PubMed ID: 12111201
[TBL] [Abstract][Full Text] [Related]
22. [Expression of bcl-2 and bax protein in uterine leiomyosarcomas and leiomyomas].
Zhang ZL; Zhang Y; Zhou JH
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Apr; 30(2):183-6. PubMed ID: 15898430
[TBL] [Abstract][Full Text] [Related]
23. Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma.
Abulafia O; Kleinhaus K; Levi G; Lee YC; Sherer DM
Gynecol Obstet Invest; 2001; 52(2):108-13. PubMed ID: 11586038
[TBL] [Abstract][Full Text] [Related]
24. [Clinical use of leuprolide acetate depot in a group of gynecologic patients in the preoperative period].
Russo P; Ciolli P; Atlante M; Carico E; Mancini R; Russo R; Vecchione A
Minerva Ginecol; 1998 Nov; 50(11):499-502. PubMed ID: 9882992
[TBL] [Abstract][Full Text] [Related]
25. Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells.
Angelucci C; Iacopino F; Lama G; Capucci S; Zelano G; Boca M; Pistilli A; Sica G
Anticancer Res; 2004; 24(5A):2729-38. PubMed ID: 15517879
[TBL] [Abstract][Full Text] [Related]
26. Relationship between platelet-derived growth factor expression in leiomyomas and uterine volume changes after gonadotropin-releasing hormone agonist treatment.
Di Lieto A; De Rosa G; De Falco M; Iannotti F; Staibano S; Pollio F; Scaramellino M; Salvatore G
Hum Pathol; 2002 Feb; 33(2):220-4. PubMed ID: 11957148
[TBL] [Abstract][Full Text] [Related]
27. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
[TBL] [Abstract][Full Text] [Related]
28. [Morphometric and histological evaluation of uterine leiomyomas treated with GnRH agonists or progestational agents].
Resta L; Sanguedolce F; Orsini G; Laricchia L; Piscitelli D; Fiore MG
Pathologica; 2004 Apr; 96(2):35-41. PubMed ID: 15449444
[TBL] [Abstract][Full Text] [Related]
29. Payer costs in patients undergoing uterine artery embolization, hysterectomy, or myomectomy for treatment of uterine fibroids.
Dembek CJ; Pelletier EM; Isaacson KB; Spies JB
J Vasc Interv Radiol; 2007 Oct; 18(10):1207-13. PubMed ID: 17911509
[TBL] [Abstract][Full Text] [Related]
30. The concentrations of collagen-associated amino acids are higher in GnRH agonist-treated uterine myomas.
Rein MS; Barbieri RL; Welch W; Gleason RE; Caulfield JP; Friedman AJ
Obstet Gynecol; 1993 Dec; 82(6):901-5. PubMed ID: 8233262
[TBL] [Abstract][Full Text] [Related]
31. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogues.
Colgan TJ; Pendergast S; LeBlanc M
Hum Pathol; 1993 Oct; 24(10):1073-7. PubMed ID: 8406417
[TBL] [Abstract][Full Text] [Related]
32. Aberrant expression of apoptosis proteins and ultrastructural aberrations in uterine leiomyomas from patients with hereditary leiomyomatosis and renal cell carcinoma.
Wortham NC; Alam NA; Barclay E; Pollard PJ; Wagner BE; Manek S; Elia G; Tomlinson IP
Fertil Steril; 2006 Oct; 86(4):961-71. PubMed ID: 16962107
[TBL] [Abstract][Full Text] [Related]
33. Morphometric and electron-microscopic analyses of the effects of gonadotropin-releasing hormone agonists on uterine leiomyomas.
Kalir T; Goldstein M; Dottino P; Brodman M; Gordon R; Deligdisch L; Wu H; Gil J
Arch Pathol Lab Med; 1998 May; 122(5):442-6. PubMed ID: 9593346
[TBL] [Abstract][Full Text] [Related]
34. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
35. Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice.
Al-Hendy A; Lee EJ; Wang HQ; Copland JA
Am J Obstet Gynecol; 2004 Nov; 191(5):1621-31. PubMed ID: 15547533
[TBL] [Abstract][Full Text] [Related]
36. Tibolone reverses the cognitive effects caused by leuprolide acetate administration, improving mood and quality of life in patients with symptomatic uterine leiomyomas.
Palomba S; Orio F; Falbo A; Oppedisano R; Tolino A; Zullo F
Fertil Steril; 2008 Jul; 90(1):165-73. PubMed ID: 18001721
[TBL] [Abstract][Full Text] [Related]
37. [Usefulness of GnRH agonists in preoperative treatment of complicated uterine myomata].
Campusano C; Zapata R; Bianchi M; Badia JI; Arteaga E
Rev Chil Obstet Ginecol; 1993; 58(2):150-4. PubMed ID: 8209044
[TBL] [Abstract][Full Text] [Related]
38. Interleukin 8 production and interleukin 8 receptor expression in human myometrium and leiomyoma.
Senturk LM; Sozen I; Gutierrez L; Arici A
Am J Obstet Gynecol; 2001 Mar; 184(4):559-66. PubMed ID: 11262453
[TBL] [Abstract][Full Text] [Related]
39. Use of GnRH agonist before hysterectomy: a cost simulation.
Bradham DD; Stovall TG; Thompson CD
Obstet Gynecol; 1995 Mar; 85(3):401-6. PubMed ID: 7862380
[TBL] [Abstract][Full Text] [Related]
40. Gonadotropin-releasing hormone analogues inhibit leiomyoma extracellular matrix despite presence of gonadal hormones.
Malik M; Britten J; Cox J; Patel A; Catherino WH
Fertil Steril; 2016 Jan; 105(1):214-24. PubMed ID: 26409322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
